SCHOLAR ROCK HOLDING CORPORATION (SRRK) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -406.36M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 207.41M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-406.36M | $0.00 | (m) | $207.41M | (m) | (m) |
| 2026-03-31 | $-409.57M | (m) | (m) | $211.58M | (m) | (m) |
| 2025-12-31 | $-384.64M | $0.00 | (m) | $208.44M | (m) | (m) |
| 2025-09-30 | $-362.11M | (m) | (m) | $211.93M | (m) | (m) |
| 2025-06-30 | $-323.34M | (m) | (m) | $210.16M | (m) | (m) |
| 2025-03-31 | $-270.73M | (m) | (m) | $190.13M | (m) | (m) |
| 2024-12-31 | $-252.05M | (m) | (m) | $184.55M | (m) | (m) |
| 2024-09-30 | $-230.73M | (m) | (m) | $169.15M | (m) | (m) |
| 2024-06-30 | $-209.62M | (m) | (m) | $150.76M | (m) | (m) |
| 2024-03-31 | $-189.21M | (m) | (m) | $135.26M | (m) | (m) |
| 2023-12-31 | $-171.29M | (m) | (m) | $121.90M | (m) | (m) |
| 2023-09-30 | $-163.69M | (m) | (m) | $116.55M | (m) | (m) |
| 2023-06-30 | $-163.88M | (m) | (m) | $119.61M | (m) | (m) |
| 2023-03-31 | $-167.95M | (m) | (m) | $124.81M | (m) | (m) |
| 2022-12-31 | $-134.37M | $33.19M | (m) | $124.44M | (m) | -404.81% |
| 2022-09-30 | $-129.31M | $37.24M | (m) | $123.88M | (m) | -347.20% |
| 2022-06-30 | $-122.52M | $42.71M | (m) | $121.75M | (m) | -286.89% |
| 2022-03-31 | $-109.65M | $47.30M | (m) | $115.28M | (m) | -231.81% |
| 2021-12-31 | $-129.92M | $18.82M | (m) | $108.47M | (m) | -690.48% |
| 2021-09-30 | $-120.66M | $18.20M | (m) | $101.20M | (m) | -662.86% |
| 2021-06-30 | $-107.20M | $15.78M | (m) | $88.31M | (m) | -679.53% |
| 2021-03-31 | $-96.39M | $15.08M | (m) | $79.71M | (m) | -639.16% |
| 2020-12-31 | $-86.88M | $15.40M | (m) | $74.06M | (m) | -564.03% |
| 2020-09-30 | $-73.12M | $19.54M | (m) | $66.35M | (m) | -374.21% |
| 2020-06-30 | $-66.61M | $21.28M | (m) | $63.66M | (m) | -313.06% |
| 2020-03-31 | $-60.53M | $22.42M | (m) | $60.38M | (m) | -270.04% |
| 2019-12-31 | $-54.54M | $20.49M | (m) | $54.22M | (m) | -266.16% |
| 2019-09-30 | $-57.76M | $12.92M | (m) | $50.28M | (m) | -447.05% |
| 2019-06-30 | $-51.88M | $8.14M | (m) | $42.64M | (m) | -636.97% |
| 2019-03-31 | $-53.38M | (m) | (m) | $40.35M | (m) | (m) |
| 2018-12-31 | $-50.69M | $0.00 | (m) | $36.31M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $-25.03M | (m) | (m) | $19.94M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |